Bristol Myers Squibb at #ASH23 (Max Gelman for Endpoints News)
Bristol Myers and 2seventy bio's Abecma survival data raise questions ahead of FDA’s advisory committee meeting: #ASH23
SAN DIEGO — The FDA in November delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for earlier …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.